Cerevia Neurosciences is developing Ladybug, a non-invasive neuromodulation platform for dementia and cognitive impairment. The company sits within therapeutic neuromodulation, with a focus on restoring impaired brain-network function through targeted stimulation. Its approach brings together imaging, stimulation, and adaptive software in an early translational platform for cognitive disorders.

The platform combines TMS-based stimulation with fMRI-guided targeting, AI-enabled personalization, and closed-loop network modulation. Public materials describe a compact mobile system intended to make image-guided neuromodulation more accessible across academic centers, neurology clinics, assisted-living facilities, and memory-care settings.

Cerevia is a spin-out of Weinberg Medical Holdings and is backed by non-dilutive federal funding and a patent portfolio tied to imaging and neuromodulation. The company is best understood as an early-stage dementia neuromodulation developer combining fMRI-informed targeting, adaptive stimulation, and point-of-care deployment logic.